<DOC>
	<DOCNO>NCT01186263</DOCNO>
	<brief_summary>The purpose study assess predictive value 99mTechnetium ( Tc ) - label albumin macroaggregates ( MAA ) microspheres ( B20 ) inject common hepatic artery distribution 90Yttrium- Selective Internal Radiotherapy ( SIRT ) -spheres ( SIR- sphere ) .</brief_summary>
	<brief_title>Predictive Value 99mTc- Albumin Spheres Before 90Y- SIR Therapy</brief_title>
	<detailed_description>Patients metastases colorectal tumor include study provide schedule 90Y SIR sphere therapy clinical reason . Before 90Y SIR sphere therapy , patient receive diagnostic examination injection MAA ( group A ) B20 ( group B ) common hepatic artery rule relevant shunt volume lung extra-hepatic location ( e.g. , stomach ) recommend manufacturer . After diagnostic scan , therapy SIR- sphere conduct 2 separate session selective injection 90Y label SIR sphere right leave hepatic artery two separate occasion ( routine procedure University Magdeburg , Germany ) . In addition , therapeutic session include selective injection MAA B20 right / leave hepatic artery accord predefined plan ( either alone mixture SIR spheres ) .The intra-hepatic distribution 90Y label SIR sphere assess use `` Bremsstrahlen '' - Single- Photon- Emission- Computed- Tomography ( SPECT ) - imaging , distribution MAA B20 assess use SPECT imaging .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>age : 18 85 year female , postmenopausal surgically sterilize liver metastasis colorectal tumor liver lobe schedule therapy 90Y SIR sphere clinical reason life expectancy longer 6 month willing able undergo study procedure voluntarily provide write fully inform consent present contraindication 90Y SIR sphere therapy variant arterial hepatic blood supply interfere objective study ( e.g. , variant Michel ) woman pregnant , lactate childbearing potential patient clinically unstable uncooperative , investigator 's opinion contraindication SIRT treatment concomitant chemotherapy shunt lung &gt; 10 % shunt extrahepatic organ ( except lung ) previously enrol study participate another prospective clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>MAA</keyword>
	<keyword>B20</keyword>
	<keyword>SIR sphere</keyword>
	<keyword>SPECT</keyword>
	<keyword>intra-hepatic distribution</keyword>
</DOC>